NTV Asset Management LLC Sells 200 Shares of Novo Nordisk A/S (NYSE:NVO)

NTV Asset Management LLC lowered its position in Novo Nordisk A/S (NYSE:NVO) by 2.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 7,300 shares of the company’s stock after selling 200 shares during the period. NTV Asset Management LLC’s holdings in Novo Nordisk A/S were worth $755,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Jennison Associates LLC increased its position in shares of Novo Nordisk A/S by 100.3% during the third quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock worth $2,129,761,000 after acquiring an additional 11,727,507 shares in the last quarter. FMR LLC boosted its stake in Novo Nordisk A/S by 122.7% during the 3rd quarter. FMR LLC now owns 12,077,501 shares of the company’s stock valued at $1,098,328,000 after purchasing an additional 6,654,614 shares during the last quarter. Morgan Stanley raised its stake in shares of Novo Nordisk A/S by 96.5% in the third quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock worth $838,021,000 after purchasing an additional 4,526,199 shares during the last quarter. Loomis Sayles & Co. L P lifted its holdings in shares of Novo Nordisk A/S by 91.7% in the third quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock valued at $827,354,000 after purchasing an additional 4,350,862 shares in the last quarter. Finally, Polen Capital Management LLC purchased a new position in shares of Novo Nordisk A/S during the third quarter valued at approximately $718,995,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on NVO shares. UBS Group assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating on the stock. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective for the company. BMO Capital Markets assumed coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Trading Down 0.8 %

Shares of NYSE:NVO traded down $0.97 on Friday, reaching $123.05. 5,932,926 shares of the company traded hands, compared to its average volume of 3,905,318. The stock has a market capitalization of $552.19 billion, a P/E ratio of 42.43, a price-to-earnings-growth ratio of 2.06 and a beta of 0.43. The business’s 50-day simple moving average is $127.20 and its 200 day simple moving average is $113.10. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 92.21%. The company had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.32 EPS for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.